GenomeNext makes access to its NGS patent portfolio readily available through licensing programs.
We license laboratories to utilize our proprietary NGS parallelization methods for human and non-human diagnostic testing, and offer companies rights to develop and commercialize NGS products that incorporate our patented parallelization technologies.
GenomeNext’s out-licensing programs encompass not only the field of diagnostics but that of activities related to research, development and improvement of products and processes for human and non-human applications as well.
Parallelization Methods are licensed for research, diagnostic and commercial use under U.S. Patent No. 9,552,458 and corresponding claims in its non-U.S. counterparts, owned by GenomeNext, LLC.
License rights to practice patented parallelization methods under the foregoing GenomeNext patents may be obtained through (i) execution of a Services Agreement from GenomeNext, LLC, (ii) acceptance of the click-wrap license and use of GenomeNext’s Olympus Platform through www.genomenext.com, or (iii) license rights from GenomeNext, LLC.
Further information on licensing may be obtained from the GenomeNext Licensing Team.
Please use the form below to request more information.